Elraglusib
Elraglusib blocks a kinase that helps pancreatic cancer resist chemotherapy; in a randomised phase 2 it lengthened survival when added to gemcitabine and nab-paclitaxel, and a phase 3 is planned.
Overview
Actuate Therapeutics developed elraglusib from a series of GSK-3 beta inhibitors. In the Actuate 1801 study, part 3B randomised patients with untreated metastatic pancreatic adenocarcinoma to gemcitabine and nab-paclitaxel with or without elraglusib.
The company reported that adding elraglusib improved overall survival and one-year survival, with manageable added toxicity, mainly visual disturbance and fatigue. The result is from a phase 2 trial and awaits confirmation in a phase 3, which Actuate has said it is planning with regulators.
Inhibits glycogen synthase kinase 3 beta, a kinase that drives NF-kB survival signalling and chemoresistance in pancreatic cancer and dampens anti-tumour immunity.
1.Elraglusib slips into a pocket on its target.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Latest papers
topQuery for this drug: (TITLE:"Elraglusib" OR ABSTRACT:"Elraglusib" OR TITLE:"9-ING-41" OR ABSTRACT:"9-ING-41") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Elraglusib, not a curated reading list.